Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
Men’s Health Network looks forward to this becoming an additional tool in the fight against prostate cancer.
The REDUCE trial is a placebo-controlled study that evaluates whether dutasteride decreases the risk of biopsy-detectable prostate cancer.
As this disease continues to strike one in six American men, with African American men having an incidence rate up to 60% higher than white men, it is important that patients and physicians engage in a meaningful conversation about prostate cancer, an individual’s risk of getting the disease, and the value of early detection and prevention.
PSA is currently the most effective tool physicians and patients have to detect a disease that kills an estimated 28,000 men a year in the US.
In addition to the approximately 200,000 men who are diagnosed with prostate cancer each year, we must remember that the disease can have a devastating effect on entire families and communities. Spouses, significant others, and children are often emotionally, financially, and physically strained and the diagnosis reaches beyond the family to impact friendships, employers, and churches.
“It is also important to note that families can impact the prevention and early detection of prostate cancer,” said
The REDUCE trial is the first step in a paradigm shift in the way prostate cancer is viewed, changing the conversation to focus on the value of prevention and early detection of this deadly disease.
SOURCE Men’s Health Network